Hepatocellular carcinoma (HCC) mortality remains high primarily due to late diagnosis as a
consequence of failed early detection. Professional societies recommend semi‐annual HCC …

The most common primary liver cancer is hepatocellular carcinoma (HCC), and its mortality
rate is increasing globally. The overall 5-year survival of patients with liver cancer is …

Background GALAD score, comprising five clinical parameters, is a predictive model
developed for hepatocellular carcinoma (HCC) detection. Since its emergence, its …

Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related mortality worldwide.
Early detection of HCC enables patients to avail curative therapies that can improve patient …

Hepatocellular carcinoma (HCC) is one of the most common and deadly tumors worldwide.
Management of HCC depends on reliable biomarkers for screening, diagnosis, and …

Hepatocellular carcinoma (HCC) is the most common primary liver tumor and is associated
with high mortality rates. Approximately 80% of cases occur in cirrhotic livers, posing a …

Serum a-fetoprotein (AFP), a well-established biomarker for hepatocellular carcinoma
(HCC), increases the sensitivity of ultrasound-based surveillance programs for early stage …

Background Hepatocellular carcinoma (HCC) risk prediction models may provide a more
personalised approach to surveillance for HCC among patients with cirrhosis. This …

Background Hepatocellular carcinoma occurs mostly in people with chronic liver disease
and ranks sixth in terms of global incidence of cancer, and fourth in terms of cancer deaths …

Alpha-fetoprotein (AFP) is a glycoprotein that plays an important role in immune regulation
with critical involvement in early human development and maintaining the immune balance …